Abstract: The present invention relates to an agent for inhibiting decomposition of a biologically active peptide by a digestive enzyme, which is aminoalkyl methacrylate copolymer E as an effective ingredient, and an agent for reducing viscosity of the gastrointestinal mucosa and mucous layers distributed over this mucosa. The present invention relates to a method for inhibiting decomposition of a biologically active peptide by a digestive enzyme, or a method for reducing viscosity of the gastrointestinal mucosa and/or mucous layers distributed over the mucosa, by administration of aminoalkyl methacrylate copolymer E. Furthermore, the present invention relates to a pharmaceutical composition for oral use with improved absorption, which comprises a biologically active peptide and aminoalkyl methacrylate copolymer E.

Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

Abstract: The present invention proposes a method of inducing both vaccine antigen-specific antibody in blood and vaccine antigen-specific antibody secreted at the mucosal surface using vaccine antigen and adjuvant of said vaccine antigen.

Abstract: A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects.

Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.

Abstract: The present invention proposes a method of inducing both vaccine antigen-specific antibody in blood and vaccine antigen-specific antibody secreted at the mucosal surface using vaccine antigen and adjuvant of said vaccine antigen.

Abstract: This invention relates to the provision of a composition for sustained release injections, wherein a physiologically active protein is spray-dried while keeping its physiological activity, this is incorporated in a biodegradable polymer with a high efficiency, and reduction of its initial burst and continuous dissolution thereof for a prolonged period of time are attained. Also, the invention relates to a physiologically active protein-containing composition for sustained release injections, which comprises a physiologically active protein and a saccharide as substantial composing components, wherein a spray-dried fine powder, 90% or more of which has a particle diameter of 10 &mgr;m or less, is dispersed in an organic solvent solution of a biodegradable polymer, and said organic solvent is removed in an oil.

Abstract: The present invention relates to an agent for inhibiting decomposition of a biologically active peptide by a digestive enzyme, which is aminoalkyl methacrylate coplolymer E as an effective ingredient, and an agent for reducing viscosity of the gastrointestinal mucosa and mucous layers distributed over this mucosa. The present invention relates to a method for inhibiting decomposition of a biologically active peptide by a digestive enzyme, or a method for reducing viscosity of the gastrointestinal mucosa and/or mucous layers distributed over the mucosa, by administration of aminoalkyl methacrylate copolymer E. Furthermore, the present invention relates to a pharmaceutical composition for oral use with improved absorption, which comprises a biologically active peptide and aminoalkyl methacrylate copolymer E.

Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.